Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of insulin degludec/insulin aspart vs Ryzodeg in type 2 diabetes
CTR20255168Phase 3Active
- Sponsor
- The United Laboratories International Holdings
- Start
- Mar 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM), sponsored by The United Laboratories International Holdings. Started Mar 2026; status: active.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20255168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255168.